Message from the CEO

During the last year, IBT passed the most important milestones in the company's history. The company's pharmaceutical candidate, IBP-9414, for the prevention of necrotizing enterocolitis, has in a concluded safety and tolerability study demonstrated a similar safety and tolerability profile in the active and placebo groups. With these results, we have the prerequisites to conduct a phase III clinical study, named "The Connection Study".

As previously communicated, IBT had capital requirements to carry out the planned phase III study and the company has evaluated several different financing alternatives, namely licensing of the pharmaceutical candidate and new share issues.

During the fourth quarter, IBT raised SEK 104.5m in a directed share issue to institutional investors. The EGM resolved on January 8, 2018, to carry out a new share issue amounting to approximately SEK 440m which was fully subscribed on January 31.

The total capital generated amounted to approximately SEK 544m prior to transaction costs and approximately SEK 528m after transaction costs which is deemed sufficient to conduct the planned phase III clinical study, as well as to fund the company's activities until market approval.

In our estimation, the phase III study will commence with the first patient recruitment during the spring of 2018.

IBT has filed an application to admittance for trading on the main marketplace, Nasdaq Stockholm. The listing change, based on preparations performed, is in IBT's estimation expected to be approved during the spring of 2018.

Staffan Strömberg
CEO

Significant events during the fourth quarter

• A directed share issue to eight institutional investors, two foreign and six Swedish, was registered on November 30 which generated SEK 104.5m prior to transaction costs
• Infant Bacterial Therapeutics and the principal investigator Dr. Josef Neu presented data on December 11 from its Safety and Tolerability study in premature infants at the Hot Topics in Neonatology Conference in Washington, D.C., USA

Significant events during the reporting period January – December 2017

• In January 2017, all 120 patients were included in the Company's clinical safety and tolerability study in IBP-9414 (NCT02472769)
• IBT's series B shares were listed on Nasdaq First North Premier on March 14
• Eva Idén and Anthon Jahreskog were elected new board members at the AGM on May 4
• The subsidiary IBT Baby AB was established in May for administration of a new share based incentive program
• All personnel subscribed for their respective allotments in a new share based incentive program
• Infant Bacterial Therapeutics ("IBT") reported results from the safety and tolerability study for IBP-9414 on September 11. The results show a similar safety and tolerability profile in the active group as in the placebo group in IBT's clinical safety and tolerability study on IBP-9414 (NCT02472769)
• IBT reported on September 28 that The European Medicines Agency's (EMA) paediatric committee (PDCO) approved IBT's proposed "paediatric investigation plan (PIP) for IBP-9414 in prevention of necrotizing enterocolitis (NEC)"

    
Significant events after the reporting period

• On January 8, 2018, the EGM decided on a preferred new share issue amounting to SEK 439.1m prior to transaction costs and on January 31 it was fully subscribed.

Infant Bacterial Therapeutics AB (publ) Interim Report is now available on the company's website www.ibtherapeutics.com.

About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) ("IBT") is a pharmaceutical company with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therapeutics and its well-developed knowledge of the action of Lactobacillus reuteri, IBT is developing its lead drug candidate IBP-9414, to prevent necrotizing enterocolitis ("NEC"), a fatal, rare disease that can afflict premature infants. The FDA and the European Commission have granted IBT Orphan Drug Designation, and the FDA have granted Rare Pediatric Disease Designation for IBP-9414 for the prevention of NEC.

IBT is further pursuing a second rare disease programme IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.

IBT is listed on Nasdaq First North Premier with Erik Penser Bank as Certified Adviser.
www.ibtherapeutics.com

For additional information please contact
Staffan Strömberg, CEO
Infant Bacterial Therapeutics AB
Bryggargatan 10
111 21 Stockholm
Phone: +46 8 410 145 55
info@ibtherapeutics.com
www.ibtherapeutics.com

Publication
This information is information that Infant Bacterial Therapeutics AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 08.00 CET on February 28, 2018.

PR 20180228 Q4 ENG
IBT Q42017 ENG

—
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Infant Bacterial Therapeutics AB via Globenewswire

PR 20180228 Q4 ENG

IBT Q42017 ENG